创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿

新浪基金07-02

今日，一则重磅合作消息落地，或为创新药板块行情再添新的上行动能。某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2648579477?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-02 13:17","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2648579477","market":"hk","top_or_hot":-1,"title":"创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿","media":"新浪基金","content":"<div>\n<p>今日，一则重磅合作消息落地，或为创新药板块行情再添新的上行动能。某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。\n　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64...</p>\n\n<a href=\"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 13:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml><strong>新浪基金</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今日，一则重磅合作消息落地，或为创新药板块行情再添新的上行动能。某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。\n　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64...</p>\n\n<a href=\"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0310800379.SGD","symbol_name":"FTIF - Templeton Global A Acc SGD","start_time":0,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml","article_id":"2648579477","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648579477","pubTimestamp":1782969420,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64亿元，创下今年4月3日之后阶段新高，最新规模24.48亿元，场内流动性表现较亮眼。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","520500":"恒生创新药ETF华泰柏瑞","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK1574":"生物医药B类股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","AZN":"阿斯利康","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4007":"制药","BK1161":"生物科技","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","06978":"永泰生物-B","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4568":"美国抗疫概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"Innovative pharmaceutical companies join hands with AstraZeneca to reach a heavy international cooperation! Huatai-PineBridge, the only Hang Seng innovative drug ETF in the whole market, has a turnover of over 1 billion for 9 consecutive trading days","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"520500":1.5,"AZN":1.5,"06978":1.5,"AZNH":0.6},"content_text":"今日，一则重磅合作消息落地，或为创新药板块行情再添新的上行动能。某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。\n　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64亿元，创下今年4月3日之后阶段新高，最新规模24.48亿元，场内流动性表现较亮眼。\n　　产业资本动向同样释放积极信号，今年医药行业回购、增持热潮持续。仅6月以来便有超过20家医药公司披露或启动股份增持、回购计划，密集落地的动作彰显出产业方对行业长期成长的信心。海外方面，近日国际私募机构KKR联合Sixth Street Partners，敲定10亿美元优先股融资方案助力生物企业BridgeBio Pharma研发遗传病新药，反映出全球创新药赛道的长期价值正在被更多国际资金认可。\n　　从产业逻辑看，创新药板块正迎来三重周期共振。其一，人口老龄化趋势下，医疗健康需求具备刚性且持续增长特征；其二，国产创新药出海加速。2025年中国创新药BD出海授权交易总额达1356.55亿美元，2026年仅第一季度便突破600亿美元，接近去年全年规模的一半；其三，支付端改革持续推进，医保与商保双向互补的保障体系逐步成型，高端新药纳入商保、对接医保的路径更加畅通，多地放开医院用药数量限制，创新药临床落地与市场放量的核心堵点正逐步打通。\n　　东北证券指出，港股创新药核心龙头价值重估窗口已至，估值上修空间充足。目前港股创新药大板块处于历史估值较低位，价值重估窗口或全面打开，优先筛选具备成熟商业化收入、管线储备充足、手握FIC/BIC差异化前沿资产的头部药企，向上修复空间充足。\n　　据悉，恒生创新药ETF华泰柏瑞（520500）紧密跟踪的恒生创新药指数通过QDII机制投资40家港股创新药龙头企业，主要聚焦于生物制药、化学制药及原料药等中上游创新药领域，集结了一批研发实力强劲、具备发展潜力的研发驱动型企业。该ETF规模较大、流动性较优，且支持场内T+0交易，在BD兑现、盈利拐点及政策支持背景下，或是助力布局港股创新药机遇的便捷工具。\n　　恒生创新药ETF华泰柏瑞（520500）的管理人华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞（510300）、A500ETF华泰柏瑞（563360）等投向透明、交易便捷、费率低廉的指数工具。截至2026年3月末，公司旗下ETF近两年累计为持有人盈利超2234亿元，是同期A股全市场仅有的三家累计盈利超两千亿元的公募基金公司之一。\n\nMACD金叉信号形成，这些股涨势不错！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：石秀珍 SF183","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648579477","isCrawlerRequest":true}